E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Coronavirus disease 2019 (COVID-19), also known as SARS-CoV-2 infection |
|
E.1.1.1 | Medical condition in easily understood language |
Novel Coronavirus 2019 infection |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10084268 |
E.1.2 | Term | COVID-19 |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Primary objective: To determine the effectiveness of the active arm(s) in preventing symptomatic (i.e. any of the following: cough, shortness of breath or difficulty breathing, fever, chills, muscle pain, sore throat, new loss of taste or smell, nausea, vomiting, or diarrhea), laboratory test-confirmed COVID-19 in healthcare workers with repeated exposures to SARS-CoV-2 by day 60 after receiving treatment intervention. |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives: 1. To determine the effectiveness of the treatment arm(s) in mitigating the severity of COVID-19 in healthcare workers who become infected with SARS-CoV-2 by day 60 after receiving trial intervention. Severity will be graded on a simplified Ordinal WHO COVID-19 severity scale.
2. To determine the effectiveness of the trial interventions in preventing/reducing the incidence of SARS-CoV-2 infection (by serology) over up to 5 months of follow-up. |
|
E.2.3 | Trial contains a sub-study | No |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Title: Hydroxychloroquine to reduce the likelihood of developing COVID-19 in non-healthcare workers. Version: 2.0 Date: 12 May 2020 The aims of this sub-study are to determine if the following endpoints in exposed factor workers who are not following recommended social distancing are effective.
Primary endpoint 1: If hydroxychloroquine is effective at preventing COVID-19 (a WHO score 1 or above).
Secondary endpoint: The minimum effective dosing schedule of hydrochloroquine for preventing COVID-19 and/or mitigating severity in onset of the disease.
The study design will be identical to the main study. The differences are that this sub-study is taking place only in UK factory workers at two sites and that the primary endpoint will be diagnosis of COVID-19, whether symptomatic or not. |
|
E.3 | Principal inclusion criteria |
1.Volunteers without clinical evidence of COVID-19 infection aged 18 years and older. 2.Healthcare workers based in a primary, secondary or tertiary healthcare settings with a high risk of developing COVID-19 due to their potential exposure to patients with SARS-CoV-2 infection. 3.The participant must have a mobile phone and access to the Internet for data collection purposes. 4.Participants who are willing and able to provide informed consent via an electronic consent process.
|
|
E.4 | Principal exclusion criteria |
1.Weight outside range 50 kg – 120 kg (110 lbs – 265 lbs). 2.Prior enrolment into other COVID-19 interventional prevention or treatment trials (observational trials not excluded). 3.Self-reported or diagnosed current infection with SARS-CoV-2 or previous COVID-19 diagnosis. 4.Self-reported current acute respiratory infection. 5.Concurrent and/or recent involvement in other research or use of the investigational product/s, a product considered to be equivalent to the investigational product/s, or any other product that is likely to interfere with the investigational products in this trial used within three months of study enrolment. 6.Self-reported known allergies to any of the IMPs and excipients of the IMPs and placebo. 7.Self-reported presence or history of the conditions listed in the appendix relevant to that IMP 8.Self-reported current use of medication with known to interact with any of the medications listed in the appendices. 9.Inability or unwillingness to be followed up for the trial period
The following additional exclusion criteria, listed in the appendices, are applicable to the MMR intervention arm: 1. pregnant women 2. Individuals receiving high dose corticosteroids, other immuno-suppressive drugs, alkylating agents or anti-metabolites 3. individuals undergoing radiotherapy 4. any malignant disease either untreated or currently undergoing therapy 5. History of administration of gammaglobulin or blood transfusions within the previous 3 months. 6. Participants with an allergy to the MR (MMR) vaccine or its components, including neomycin. 7. Idiopathic thrombocytopenic purpura (ITP) 8. Untreated tuberculosis 9. Prior receipt of any vaccines (licensed or investigational) ≤30 days before enrollment 10. Planned receipt of a live attenuated vaccine [e.g. oral polio vaccine, inhaled influenza vaccine, BCG] or a vaccine for SARS-CoV-2 within 30 days after the study vaccination. Planned receipt of an inactivated influenza vaccine (via injection) is not an exclusion criterion 11. Prior receipt of an investigational or licensed vaccine likely to impact on interpretation of the trial data (e.g. Adenovirus vectored vaccines, any coronavirus vaccines). 12. Any confirmed or suspected immunosuppressive or immunodeficient state, including untreated HIV infection with a CD4T count <200 /mL 13. Asplenia
As new arms are added new eligibility criteria will be listed in the appendices. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Symptomatic COVID-19: Clinical diagnosis of COVID-19 with laboratory confirmation (i.e. based on viral PCR), and symptoms of COVID-19 (cough, shortness of breath or difficulty breathing, fever, chills, muscle pain, sore throat, new loss of taste or smell, nausea, vomiting, or diarrhea) by day 60 after receiving treatment intervention. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The final analysis of the primary endpoint will take place once all study participants have reached their primary endpoint 60 days after commencement of trial intervention.
In addition, this Bayesian trial will perform frequent interim analyses for efficacy, futility and harm. This means that the DMC will regularly consider the balance of benefit and risk. Strong evidence of benefit, futility, or harm will result in the advice to modify or stop the trial.
|
|
E.5.2 | Secondary end point(s) |
Secondary endpoint of special interest: Severity of COVID-19 over the study period using the WHO scoring system 0 to 8 where 0 is uninfected and 8 is death.
Secondary endpoints: ● Primary endpoint, but instead of the 60-day time-window, over the course of the first 30 days of treatment ● Symptomatic COVID-19 (with subsequent virological confirmation) during the 5-month study period. ● Incident COVID-19 during the 60-day study period, which includes asymptomatic infections identified by serology samples taken at the time-point of study exit.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary outcomes will be evaluated at interim analyses and at the end of the trial once the recruitment and follow-up period has completed and all the data from the last participants last visit has been received.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 30 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 30 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is defined as five months after the last participant is enrolled when the database is locked, and all queries are resolved. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |